DE60304477T2 - Verbessertes transdermales abgabesystem für die verabreichung von rotigotin - Google Patents

Verbessertes transdermales abgabesystem für die verabreichung von rotigotin Download PDF

Info

Publication number
DE60304477T2
DE60304477T2 DE60304477T DE60304477T DE60304477T2 DE 60304477 T2 DE60304477 T2 DE 60304477T2 DE 60304477 T DE60304477 T DE 60304477T DE 60304477 T DE60304477 T DE 60304477T DE 60304477 T2 DE60304477 T2 DE 60304477T2
Authority
DE
Germany
Prior art keywords
rotigotine
matrix
tds
adhesive
microreservoirs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60304477T
Other languages
German (de)
English (en)
Other versions
DE60304477D1 (de
Inventor
Mike Woodstown HANNAY
Wilhelm Dietrich SCHACHT
Hans-Michael Wolff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Publication of DE60304477D1 publication Critical patent/DE60304477D1/de
Application granted granted Critical
Publication of DE60304477T2 publication Critical patent/DE60304477T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60304477T 2002-07-30 2003-07-28 Verbessertes transdermales abgabesystem für die verabreichung von rotigotin Expired - Lifetime DE60304477T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02016860A EP1386605A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system for the administration of rotigotine
EP02016860 2002-07-30
PCT/EP2003/008320 WO2004012730A1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system for the administration of rotigotine

Publications (2)

Publication Number Publication Date
DE60304477D1 DE60304477D1 (de) 2006-05-18
DE60304477T2 true DE60304477T2 (de) 2006-12-14

Family

ID=30011090

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60304477T Expired - Lifetime DE60304477T2 (de) 2002-07-30 2003-07-28 Verbessertes transdermales abgabesystem für die verabreichung von rotigotin

Country Status (19)

Country Link
EP (2) EP1386605A1 (cg-RX-API-DMAC7.html)
JP (2) JP4837916B2 (cg-RX-API-DMAC7.html)
KR (1) KR101016838B1 (cg-RX-API-DMAC7.html)
CN (2) CN1671375A (cg-RX-API-DMAC7.html)
AT (1) ATE322263T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003258539B2 (cg-RX-API-DMAC7.html)
BR (1) BR0313091A (cg-RX-API-DMAC7.html)
CA (1) CA2491366A1 (cg-RX-API-DMAC7.html)
DE (1) DE60304477T2 (cg-RX-API-DMAC7.html)
DK (1) DK1524975T3 (cg-RX-API-DMAC7.html)
ES (1) ES2256780T3 (cg-RX-API-DMAC7.html)
IL (1) IL165918A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05000350A (cg-RX-API-DMAC7.html)
NO (1) NO333297B1 (cg-RX-API-DMAC7.html)
PL (1) PL217079B1 (cg-RX-API-DMAC7.html)
PT (1) PT1524975E (cg-RX-API-DMAC7.html)
SI (1) SI1524975T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004012730A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200500252B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014198423A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Dreischichtiges transdermales therapiesystem (tts)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EP1796610A4 (en) * 2004-09-29 2012-12-05 Schwarz Pharma Inc TRANSDERMAL THERAPEUTIC SYSTEM FOR PARKINSON'S DISEASE
US7353034B2 (en) 2005-04-04 2008-04-01 X One, Inc. Location sharing and tracking using mobile phones or other wireless devices
CA2739380C (en) * 2008-10-06 2014-12-09 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
WO2011076879A1 (en) * 2009-12-22 2011-06-30 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
KR101558042B1 (ko) * 2012-07-05 2015-10-07 에스케이케미칼주식회사 로티고틴을 함유한 경피흡수제제
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
WO2014198422A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
CN106456567A (zh) * 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
JP6573913B2 (ja) * 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
KR102364378B1 (ko) 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
CN104382850B (zh) * 2014-10-17 2017-12-22 烟台大学 一种罗替戈汀微乳及微乳凝胶
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
PT1256340E (pt) * 2001-05-08 2003-12-31 Sanol Arznei Schwarz Gmbh Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014198423A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Dreischichtiges transdermales therapiesystem (tts)

Also Published As

Publication number Publication date
CN1671375A (zh) 2005-09-21
EP1524975A1 (en) 2005-04-27
NO333297B1 (no) 2013-04-29
SI1524975T1 (sl) 2006-06-30
PL217079B1 (pl) 2014-06-30
AU2003258539B2 (en) 2008-08-21
EP1386605A1 (en) 2004-02-04
CN101953819A (zh) 2011-01-26
KR101016838B1 (ko) 2011-02-22
DE60304477D1 (de) 2006-05-18
EP1524975B9 (en) 2012-02-22
ZA200500252B (en) 2006-01-25
PL374814A1 (en) 2005-10-31
PT1524975E (pt) 2006-07-31
BR0313091A (pt) 2005-06-21
JP2005535687A (ja) 2005-11-24
KR20050056942A (ko) 2005-06-16
CA2491366A1 (en) 2004-02-12
NO20050472L (no) 2005-01-27
ATE322263T1 (de) 2006-04-15
MXPA05000350A (es) 2005-03-31
ES2256780T3 (es) 2006-07-16
IL165918A0 (en) 2006-01-15
JP5564469B2 (ja) 2014-07-30
JP4837916B2 (ja) 2011-12-14
EP1524975B1 (en) 2006-04-05
DK1524975T3 (da) 2006-07-31
JP2011219485A (ja) 2011-11-04
WO2004012730A1 (en) 2004-02-12
AU2003258539A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
EP1033978B1 (de) D2-agonist enthaltendes transdermales therapeutisches system zur behandlung des parkinson-syndroms und verfahren zu seiner herstellung
DE60021099T2 (de) Transdermale, in form einer haftschicht ausgebildete zweifachmedikamenten-verabreichungsvorrichtung
DE3785015T2 (de) Elastische Vorrichtung zur transdermalen Wirkstofffreisetzung und Zusammensetzungen und Vorrichtungen, die Fettsäureester/-äther oder Alkandiole als Absortionssteigerer verwenden.
EP0695177B1 (de) Wirkstoffplaster
EP1103260B1 (de) Transdermalsystem zur Abgabe von Clonidin
EP1178782B1 (de) Transdermales therapeutisches system (tts) tolterodin enthaltend
KR101016838B1 (ko) 로티고틴 투여를 위한 향상된 경피 송달 시스템
DE60100994T2 (de) Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
EP2295046B1 (de) Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff davon
DE60311449T2 (de) Transdermales therapeutisches system mit zwei übereinanderliegenden matrixschichten, die verschiedene affinitäten zum enthaltenen wirkstoff ausweisen
WO2004058247A1 (de) Vorrichtung zur transdermalen verabreichung von rotigotin-base
EP2797588B1 (de) Transdermales therapeutisches system mit geringer neigung zur spontankristallisation
EP2111857A1 (de) Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
EP1347749A2 (de) Transdermales therapeutisches system mit dem wirkstoff oxybutynin
EP0665745B1 (de) Pflaster zur transdermalen verabreichung von flüchtigen, pharmazeutisch wirksamen, chemisch basischen inhaltsstoffen und verfahren zu seiner herstellung
DE60309329T2 (de) Verbessertes transdermales abgabesystem
WO2005011687A1 (de) Transdermales therapeutisches system mit dem wirkstoff pramipexol
DE3587698T2 (de) Pharmazeutische Präparate.
EP1480625A1 (de) Transdermalsystem mit fentanyl
EP0379933B1 (de) Superfizielles therapeutisches System mit einem Gehalt an einem antineoplastischen Wirkstoff, insbesondere 5-Fluoruracil
EP2366388A1 (de) Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin
EP4093383B1 (de) Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber
DE112024000733T5 (de) Transdermales therapeutisches system zur transdermalen verabreichung von huperzin a
EP3200774A1 (de) Transdermales therapeutisches system mit rotigotin zur behandlung von morbus parkinson
WO2020025695A1 (de) Transdermales therapeutisches system zur abgabe von scopolamin ohne membran

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UCB PHARMA GMBH, 40789 MONHEIM, DE